Revenue surged 428% year-over-year to €7.4 million, driven by milestone payments, while operating expenses fell 32% due to restructuring. Net loss narrowed to €3.4 million, and cash reach was extended to mid-2027 after a $20 million upfront from Soleus Capital.Original document: Heidelberg Pharma A…
Revenue surged 428% year-over-year to €7.4 million, driven by milestone payments, while operating expenses fell 32% due to restructuring. Net loss narrowed to €3.4 million, and cash reach was extended to mid-2027 after a $20 million upfront from Soleus Capital.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.